Novel Endothelial Adhesion Molecule for Monocytes
The invention consists of the ability to treat inflammatory and autoimmune disorders by blocking the ablility of endothelial cells expressing the LM151 antigen, or other mammalian homologues thereof, to bind circulating monocytes, theus alteringn leukocyte recruitment from the blood and modulating local inflammatory responses. The invention also permits targeting of immunomodulatory agents or cytokines to inflamed enfothelium in vivo, through induced expression of the LM151 antigen.
The invention is applicable to the modulation of inflammation, in a variety of clinically important disease states, involving acute, subacute, and chronic inflammation, and atherosclerosis.
U.S. Patent No. 5,719,268
